Protease-Activatable AAV Capsid Peptide Locks for Targeted Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy vectors, such as Adeno-associated viruses (AAVs), face challenges in specificity and safety due to non-targeted delivery and potential health risks during production and clinical use, particularly in targeting diseased tissues like tumors.
Innovation Solution
The development of protease-activatable AAV vectors with genetically encoded peptides, known as peptide locks, which block biologically active domains on the virus capsid surface, allowing activation only by specific enzymatic inputs like matrix metalloproteinases (MMPs) expressed in cancer cells, enhancing specificity and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If AAV vectors are used for gene therapy delivery, then transduction efficiency is improved, but specificity to diseased tissues deteriorates
Solution Approach 1:
The patent applies preliminary action by pre-installing peptide locks on the AAV capsid surface that block biologically active domains before infection. These locks are designed to be cleaved by specific proteases (such as MMP-2, MMP-9, or cathepsin B) that are overexpressed in diseased tissues. The peptide sequence is engineered with a protease recognition site that allows selective cleavage only in the presence of the target protease, thereby activating the virus only at the disease site and improving tissue-specific delivery.
Solution Approach 2:
The patent implements local quality by modifying specific regions of the AAV capsid surface with protease-sensitive peptide sequences. The peptide locks are positioned at specific locations on the capsid (such as on VP1, VP2, or VP3 proteins) where they can effectively block receptor binding sites. This localized modification ensures that the activation mechanism is confined to specific molecular interactions at the virus-receptor interface, enabling precise control over where and how the virus becomes active.
2Measurement precision
If peptide locks are added to AAV capsid to improve specificity, then device complexity increases
Solution Approach 1:
The patent applies the nested doll principle by embedding the peptide lock sequences within the existing AAV capsid protein structures. The peptide locks are integrated as part of the capsid protein sequences (such as fusions with VP1, VP2, or VP3 proteins) rather than being separate components. This nesting approach allows the peptide locks to be co-assembled with the capsid during viral particle formation, reducing the need for separate assembly steps and minimizing structural complexity while maintaining the ability to block and activate biologically active domains.
3Object-affected harmful factors
If protease activation is required for virus activity, then safety is improved, but ease of operation deteriorates
Solution Approach 1:
The patent implements self-service by designing the peptide locks to be automatically activated by proteases that are naturally present and overexpressed in diseased tissues. The system does not require external administration of activating agents or complex delivery protocols. Instead, the virus particles circulate in an inactive state until they encounter the target tissue, where the endogenous protease environment automatically triggers activation. This self-activating mechanism simplifies the overall procedure while maintaining safety, as the virus only becomes functional in the presence of disease-specific proteases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the specificity of gene delivery to cancer cells by requiring enzymatic activation, reducing off-target effects and increasing transduction efficiency in protease-expressing tissues while maintaining safety.
Implementation Method 1
peptides block biologically active domains on the virus capsid surface... requiring enzymatic activation... activatable by different types of proteases
Data Source
AI summary
The present invention is a peptide lock that comprises at least one peptide that is genetically encoded into the Adeno-associated virus (AAV) capsid that block biologically active domains on the virus capsid surface. The peptide lock, can be processed by biological enzymes to restore biological behavior of the capsid-displayed domains, thus ‘decoding the lock’ or opening the lock. A method of forming the peptide lock comprises providing at least one peptide, providing an Adeno-associated virus capsid and genetically inserting the at least one peptide into the Adeno-associated virus capsid to block the biologically active domains on the virus capsid surface.